Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Voglibose (Glustat) 是一种 valiolamine 的衍生物,可抑制α-葡萄糖苷酶活性,可作用于高血糖症等。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
10 mg | ¥ 219 | 现货 | ||
25 mg | ¥ 342 | 现货 | ||
50 mg | ¥ 592 | 现货 | ||
100 mg | ¥ 878 | 现货 | ||
200 mg | ¥ 1,280 | 现货 | ||
500 mg | ¥ 2,190 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 281 | 现货 |
产品描述 | Voglibose (Glustat), an N-substituted derivative of valiolamine, exhibits excellent inhibitory activity against α-glucosidases and action against hyperglycemia and various disorders caused by hyperglycemia. |
体外活性 | Voglibose can inhibit the intestinal α-glucosidases, which are responsible for the digestion of disaccharides such as maltose and sucrose, including maltase and sucrase. The Ki values of Voglibose for sucrase and maltase are about 106and 105 times smaller than the Km values for sucrose and maltose. [1] |
体内活性 | Voglibose (0.2 mg/kg) completely inhibits the insulin response to sucrose in rats. Voglibose (0.2 mg/kg) reduces the carbohydrate-induced increase in blood glucose in rats. Voglibose (0.2 mg/kg) reduces the carbohydrate-induced increase in blood glucose without causing sustained hypoglycemia in both normal and neonatal streptozotocin-induced diabetic rats. [2] Voglibose (0.001%) treatment increases GLP-1 secretion (Voglibose alone, 1.6-fold; Alogliptin plus Voglibose, 1.5-fold), while it decreases plasma glucose-dependent insulinotropic polypeptide (GIP) (Voglibose alone, 30%; Alogliptin plus voglibose, 29%) in prediabetic db/db mice after 3 weeks. Voglibose (0.001%) treatment decreases plasma DPP-4 activity by 15% in prediabetic db/db mice. Voglibose (0.001%) treatment increases plasma insulin by 1.8-fold and decreases plasma glucagon by 8% in prediabetic db/db mice. [3] Voglibose (0.001% and 0.005%) stimulates GLP-1 secretion in ob/ob mice, as evidenced by the 1.3- to 1.5-fold increase in plasma active plus inactive amidated GLP-1 levels. Voglibose (0.001% and 0.005%) decreases plasma DPP-4 activity unexpectedly by 40% to 51% in ob/ob mice, resulting from reduced plasma DPP-4 concentrations. Voglibose (0.001% and 0.005%) increases GLP-1 content by 1.5- to 1.6-fold and 1.4- to 1.6-fold in the lower intestine and colon, respectively, in ob/ob mice. [4] |
别名 | AO 128, 伏格列波糖, Glustat, Basen |
分子量 | 267.28 |
分子式 | C10H21NO7 |
CAS No. | 83480-29-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 20.1 mg/mL (75 mM)
H2O: 26.7 mg/mL (100 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / H2O | 1 mM | 3.7414 mL | 18.707 mL | 37.4139 mL | 93.5349 mL |
5 mM | 0.7483 mL | 3.7414 mL | 7.4828 mL | 18.707 mL | |
10 mM | 0.3741 mL | 1.8707 mL | 3.7414 mL | 9.3535 mL | |
20 mM | 0.1871 mL | 0.9353 mL | 1.8707 mL | 4.6767 mL | |
50 mM | 0.0748 mL | 0.3741 mL | 0.7483 mL | 1.8707 mL | |
H2O | 100 mM | 0.0374 mL | 0.1871 mL | 0.3741 mL | 0.9353 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Voglibose 83480-29-9 Metabolism Glucosidase inhibit AO-128 Inhibitor AO 128 伏格列波糖 Glustat Basen AO128 inhibitor